{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:48Z","timestamp":1786119528412,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Forty percent to 50% of acetylcholine receptor antibody-seronegative patients with myasthenia gravis have muscle-specific receptor tyrosine kinase antibodies. Many muscle-specific receptor tyrosine kinase + myasthenia gravis patients remain refractory with conventional therapies. Rituximab is an anti-CD20 monoclonal antibody used in refractory B-cell disorders. Currently there is no standard dosing schedule for rituximab. We present two muscle-specific receptor tyrosine kinase + myasthenia gravis patients clinically refractory to conventional therapy who, after a single course of rituximab, became asymptomatic and discontinued all medication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cnd.0b013e3181fcc109","type":"journal-article","created":{"date-parts":[[2010,11,15]],"date-time":"2010-11-15T23:49:42Z","timestamp":1289864982000},"page":"85-87","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Prolonged Improvement After Rituximab: Two Cases of Resistant Muscle-Specific Receptor Tyrosine Kinase + Myasthenia Gravis"],"prefix":"10.1097","volume":"12","author":[{"given":"Prinyarat","family":"Burusnukul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J","family":"Cupler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl 8","key":"R1-6-20240808","first-page":"S63","article-title":"Multicenter study of clinical, geographical and ethnic features of MuSK-antibody-associated myasthenia gravis.","volume":"56","author":"Vincent","year":"2004","journal-title":"Ann Neurol"},{"key":"R2-6-20240808","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00415-006-0442-2","article-title":"Rituximab in refractory MuSK antibody myasthenia gravis.","volume":"254","author":"Thakre","year":"2007","journal-title":"J Neurol"},{"key":"R3-6-20240808","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"key":"R4-6-20240808","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mus.21533","article-title":"Clinical findings in MuSK-antibody positive myasthenia gravis: a US experience.","volume":"41","author":"Pasnoor","year":"2010","journal-title":"Muscle Nerve"},{"key":"R5-6-20240808","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.coph.2004.03.006","article-title":"Anti B cell therapy (rituximab) in the treatment of autoimmune diseases.","volume":"4","author":"Kazkaz","year":"2004","journal-title":"Curr Opin Pharmacol"},{"key":"R6-6-20240808","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy following rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports project.","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"R7-6-20240808","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Barohn, R, Ernstoff, R, et al. Myasthenia gravis. Recommendations for clinical research standards.","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"R8-6-20240808","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s00277-005-1050-4","article-title":"Anti CD 20 antibody (rituxuimab) therapy in a myasthenia gravis patient with follicular lymphoma.","volume":"84","author":"Takagi","year":"2005","journal-title":"Ann Hematol"},{"key":"R9-6-20240808","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/mus.21521","article-title":"Rituximab in the management of refractory myasthenia gravis.","volume":"41","author":"Zebardast","year":"2010","journal-title":"Muscle Nerve online"},{"key":"R10-6-20240808","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","article-title":"Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab.","volume":"33","author":"Hain","year":"2006","journal-title":"Muscle Nerve"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00131402-201012000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:45:14Z","timestamp":1786041914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00131402-201012000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0b013e3181fcc109","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}